Amplify U.S. Alternative Harvest ETF

MJUS

Capitalización de mercado USD 61.7 M

The 'Undercovered' Dozen series highlights lesser-covered ETFs, offering insights from various authors on potential opportunities and trends in this space. The Janus Henderson AAA CLO ETF (JAAA) invests in AAA tranches of CLOs, providing lower risk through diversification and predictable outcomes, according to John Bowman. Stratos Capital Partners views the Vanguard Extended Duration Treasury ETF (EDV) as attractive for its high-yield and potential bond price appreciation as interest rates decline.

CHICAGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Amplify ETFs, a leading provider of exchange traded funds, today announced the scheduled liquidation of the Amplify U.S. Alternative Harvest ETF (NYSE Arca: MJUS) (the “Fund”). Based on the recommendation of Amplify Investments LLC, the Fund's investment adviser, the Board of Trustees of the Amplify ETF Trust unanimously determined that it is in the best interests of the Fund and its shareholders to liquidate the Fund.

Wall Street registered the best week of the year for major indexes.

CHICAGO, June 27, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs announces June income distributions for its ETFs. ETF Name Ticker   Amount per Share Ex-Date Record Date Payable Date Amplify AI Powered Equity ETF AIEQ   $0.05503 6/27/2024 6/27/2024 6/28/2024 Amplify Travel Tech ETF AWAY   $0.03617 6/27/2024 6/27/2024 6/28/2024 Amplify Cash Flow Dividend Leaders ETF COWS   $0.05711 6/27/2024 6/27/2024 6/28/2024 Amplify CWP Enhanced Dividend Income ETF DIVO   $0.15556 6/27/2024 6/27/2024 6/28/2024 Amplify Etho Climate Leadership U.S. ETF ETHO   $0.13457 6/27/2024 6/27/2024 6/28/2024 Amplify Treatments, Testing and Advancements ETF GERM   $0.08798 6/27/2024 6/27/2024 6/28/2024 Amplify Cybersecurity ETF HACK   $0.02578 6/27/2024 6/27/2024 6/28/2024 Amplify Cash Flow High Income ETF HCOW   $0.17040 6/27/2024 6/27/2024 6/28/2024 Amplify International Enhanced Dividend Income ETF IDVO   $0.15320 6/27/2024 6/27/2024 6/28/2024 Amplify BlackSwan ISWN ETF (International) ISWN   $0.14293 6/27/2024 6/27/2024 6/28/2024 Amplify Alternative Harvest ETF MJ   $0.16966 6/27/2024 6/27/2024 6/28/2024 Amplify U.S. Alternative Harvest ETF MJUS   $0.01565 6/27/2024 6/27/2024 6/28/2024 Amplify Natural Resources Dividend Income ETF NDIV   $0.13227 6/27/2024 6/27/2024 6/28/2024 Amplify BlackSwan Tech & Treasury ETF QSWN   $0.14215 6/27/2024 6/27/2024 6/28/2024 Amplify Samsung SOFR ETF SOF   $0.44497 6/27/2024 6/27/2024 6/28/2024 Amplify BlackSwan Growth & Treasury Core ETF SWAN   $0.19349 6/27/2024 6/27/2024 6/28/2024 Amplify High Income ETF YYY   $0.12000 6/27/2024 6/27/2024 6/28/2024 About Amplify ETFs Amplify ETFs, sponsored by Amplify Investments, has over $9 billion in assets across its suite of ETFs (as of 5/31/2024).

President Biden and the DOJ have officially announced the rescheduling of cannabis to Schedule III, sparking increased activity in cannabis stocks. The MJUS ETF focuses on US-based cannabis firms and has a high concentration in top operators. Rescheduling may have significant implications for cannabis companies, including the potential for normalized tax rates and increased earnings.

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

As the first quarter comes to a close, clearly, there have been some thematic winners in terms of flows and investment performance. Artificial Intelligence AI-themed ETFs remain among the top recipients of investor flows this year.

Cannabis stocks soared this year after the Department of Health and Human Services asked the US Drug Enforcement Administration to start reviewing its classification of cannabis from Schedule I to Schedule III. Positive developments are happening in Germany also.

The Magnificent Seven stocks are getting smoked by stocks coming from an unusual place: Cannabis.

One of the top-performing thematic segments this year is cannabis. A major catalyst has been the proposed descheduling of it from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA).